rethinkPeptides Search
Menu
Study breakdown

Computational Design of Cell-Penetrating Peptides to Deliver the Anti-Cancer Protein Endostatin

In VitroPreliminary evidence
The takeaway

Computer modeling identified four cell-penetrating peptides — Cyt c-ss-MAP, TP-biot1, MPGα, and DPV1047 — as optimal candidates for delivering the anti-cancer protein endostatin into cells.

4 CPPs identified

as computationally optimal carriers for endostatin delivery, with high stability and no predicted immunogenicity

What the researchers found

Four CPPs (Cyt c-ss-MAP, TP-biot1, MPGα, DPV1047) were computationally predicted to form stable, non-antigenic fusions with endostatin that could improve its delivery and overcome its clinical limitations of poor stability and low half-life.

Why it matters

Endostatin showed promise in early cancer research but failed clinically due to instability. If cell-penetrating peptides can solve this delivery problem, it could revive endostatin as an anti-cancer therapy and demonstrate a broader approach for rescuing unstable protein drugs.

The numbers in context

Multiple CPP candidates were computationally evaluated for endostatin binding and delivery characteristics.

How the study worked

Computational study using multiple bioinformatics tools: ProtParam for stability/hydrophobicity, VaxiJen for antigenicity prediction, DeepLoc-1.0 for subcellular localization, I-TASSER for 3D structure modeling, and PROCHECK/ERRAT/Verify3D/ProSA-Web for model validation.

Who was studied

Computational analysis of CPP-endostatin binding interactions

What this study cannot tell us

Entirely computational — no experimental validation in cells, animals, or humans. Computational predictions do not always match real-world behavior. CPP-fusion proteins may have unexpected toxicity, immunogenicity, or stability issues in biological systems. The transition from in silico to in vivo often reveals unforeseen challenges.

How to read the evidence

Preliminary evidence: purely computational study with no experimental validation. Results are theoretical predictions that require laboratory and eventually clinical testing.

When this study was published

Published in 2024. Uses current computational tools for peptide fusion design.

The bigger picture

Many promising protein drugs fail because they are unstable or cannot reach their targets inside cells. Cell-penetrating peptides offer a general solution — they can carry large cargo across cell membranes. This study applies computational screening to match CPPs with specific therapeutic proteins, a strategy that could accelerate peptide-based drug delivery design.

Questions still open

  • Will these CPP-endostatin fusions actually penetrate cells and maintain anti-angiogenic activity in laboratory tests?
  • Could these same CPPs be used to deliver other unstable therapeutic proteins beyond endostatin?
  • What are the safety profiles of these specific CPPs when used as delivery vehicles in animal models?

Common questions

What are cell-penetrating peptides?
Cell-penetrating peptides (CPPs) are short chains of amino acids that can cross cell membranes and carry other molecules inside. They act like molecular delivery trucks, helping therapeutic proteins reach their targets inside cells.
Why did endostatin fail as a cancer drug?
Endostatin showed promise in blocking tumor blood vessel growth, but it breaks down too quickly in the body and has difficulty reaching cancer cells. CPP fusions could solve both problems by protecting endostatin and helping it enter cells.

Read the original research

Application of Cell Penetrating Peptides for Intracellular Delivery of Endostatin: A Computational Approach.

Current computer-aided drug design, 20(3), 208-223

Citation

Zamani, Mozhdeh; Nezafat, Navid; Mokarram, Pooneh; Kadkhodaei, Behnam. (2024). Application of Cell Penetrating Peptides for Intracellular Delivery of Endostatin: A Computational Approach.. Current computer-aided drug design, 20(3), 208-223. https://doi.org/10.2174/1573409919666230426093230